Enantiospecific Reassessment of the Pharmacokinetics and Pharmacodynamics of Oral Eflornithine against Late-Stage Trypanosoma brucei gambiense Sleeping Sickness

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  2014-12-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/AAC.04101-14PMID 25512417PMCID PMC4335853
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• R: A language and environment for statistical computing.

  2014cited by this paper
• Population pharmacokinetic modeling and deconvolution of enantioselective absorption of eflornithine in the rat

  2013cited by this paper
• Implementation of dose superimposition to introduce multiple doses for a mathematical absorption model (transit compartment model)

  2012cited by this paper
• Chemotherapy for second-stage Human African trypanosomiasis.

  2010influential reference
• NECT Is Next: Implementing the New Drug Combination Therapy for Trypanosoma brucei gambiense Sleeping Sickness

  2010cited by this paper
• Determination of eflornithine enantiomers in plasma by precolumn derivatization with o-phthalaldehyde-N-acetyl-L-cysteine and liquid chromatography with UV detection.

  2009cited by this paper
• Effectiveness of melarsoprol and eflornithine as first-line regimens for gambiense sleeping sickness in nine Médecins Sans Frontières programmes.

  2009cited by this paper
• Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial.

  2009cited by this paper
• Importance of Shrinkage in Empirical Bayes Estimates for Diagnostics: Problems and Solutions

  2009cited by this paper
• Human African trypanosomiasis, chemotherapy and CNS disease.

  2009cited by this paper
• The continuing problem of human African trypanosomiasis (sleeping sickness)

  2008influential reference
• Enantioselective and Nonlinear Intestinal Absorption of Eflornithine in the Rat

  2008cited by this paper
• Human African trypanosomiasis: pharmacological re‐engagement with a neglected disease

  2007influential reference
• Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies

  2007cited by this paper
• Melarsoprol-free drug combinations for second-stage Gambian sleeping sickness: the way to go.

  2007cited by this paper
• Agreement Between Methods of Measurement with Multiple Observations Per Individual

  2007cited by this paper
• Pharmacokinetic-Pharmacodynamic Modeling and Simulation.

  2007cited by this paper
• Human African trypanosomiasis

  2006cited by this paper
• Assessing kidney function--measured and estimated glomerular filtration rate.

  2006cited by this paper
• Melarsoprol versus eflornithine for treating late-stage Gambian trypanosomiasis in the Republic of the Congo.

  2006influential reference
• Human African trypanosomiasis–neurological aspects

  2006cited by this paper
• Sleeping sickness – human African trypanosomiasis

  2005cited by this paper
• PsN-Toolkit - A collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM

  2005cited by this paper
• The pharmacokinetics of eflornithine (α-difluoromethylornithine) in patients with late-stage T.b. gambiense sleeping sickness

  2004cited by this paper
• High-performance liquid chromatographic method for determination of 2-difluoromethyl-DL-ornithine in plasma and cerebrospinal fluid.

  2003cited by this paper
• Pharmacokinetic Strategies in Deciphering Atypical Drug Absorption Profiles

  2003cited by this paper
• Current chemotherapy of human African trypanosomiasis

  2003cited by this paper
• Inhibition of human ornithine decarboxylase activity by enantiomers of difluoromethylornithine.

  2003cited by this paper
• Eflornithine for the treatment of human African trypanosomiasis

  2003cited by this paper
• General Pharmacokinetic Model for Drugs Exhibiting Target-Mediated Drug Disposition

  2001cited by this paper
• Pharmacokinetic models for the saturable distribution of paclitaxel.

  1999cited by this paper
• Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM.

  1999cited by this paper
• The significance of artificial cerebrospinal fluid as perfusate and endoneurosurgery.

  1996cited by this paper
• Eflornithine concentrations in serum and cerebrospinal fluid of 63 patients treated for Trypanosoma brucei gambiense sleeping sickness.

  1993influential reference
• Efficacy and toxicity of eflornithine for treatment of Trypanosoma brucei gambiense sleeping sickness.

  1992cited by this paper
• Kinetics of α‐difluoromethylornithine: An irreversible inhibitor of ornithine decarboxylase

  1981cited by this paper

• Pharmacokinetics of Racemic Eflornithine in Human Plasma and Cerebrospinal Fluid: Clinical Perspectives for L-eflornithine Against Human African Trypanosomiasis

  2025influential citation
• Review of the Situation of Human African Trypanosomiasis in the Republic of Congo From the 1950s to 2020

  2022cites this paper
• Population Pharmacodynamic Modeling of Eflornithine-Based Treatments Against Late-Stage Gambiense Human African Trypanosomiasis and Efficacy Predictions of L-eflornithine-Based Therapy

  2022influential citation
• Chemotherapy for second‐stage human African trypanosomiasis: drugs in use

  2021cites this paper
• Enantiospecific antitrypanosomal in vitro activity of eflornithine

  2021cites this paper
• Sleeping sickness

  2020cites this paper
• Systemic and Target-Site Pharmacokinetics of Antiparasitic Agents

  2020cites this paper
• Chiral Chromatographic Isolation on Milligram Scale of the Human African Trypanosomiasis Treatment d- and l-Eflornithine

  2020cites this paper
• Lack of Clinical Pharmacokinetic Studies to Optimize the Treatment of Neglected Tropical Diseases: A Systematic Review

  2016cites this paper